Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05027503
Other study ID # IUCbcinar01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 19, 2021
Est. completion date June 21, 2024

Study information

Verified date March 2024
Source Istanbul University - Cerrahpasa (IUC)
Contact Betül Çinar, MSc
Phone +905327879969
Email betulbirik@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cystic fibrosis (CF) is a genetic disease that affects many organs and systems, especially respiratory system problems due to lung damage. Patients often have difficulty in removing the sticky and viscous secretion that accumulates in the respiratory tract, and the risk of mortality increases with the development of respiratory failure. In patients with CF, exercise capacity, peripheral muscle strength, core endurance, flexibility, postural stability, physical activity level, and quality of life also decrease secondarily. Recently published guidelines recommend respiratory physiotherapy for coping with CF-related symptoms and recommend referral of patients to physical activity and exercise. Hippotherapy simulator is a mechanical exercise tool that imitates the walking movement of a real horse and is used to increase physical fitness parameters. This study aims to show the effects of exercises performed with a hippotherapy simulator in addition to respiratory physiotherapy on physical fitness, sputum production, physical activity and quality of life of children with CF.


Recruitment information / eligibility

Status Recruiting
Enrollment 32
Est. completion date June 21, 2024
Est. primary completion date February 19, 2024
Accepts healthy volunteers No
Gender All
Age group 8 Years to 14 Years
Eligibility Inclusion Criteria: - Be in the 8-14 age range - To be diagnosed with cystic fibrosis according to the American Cystic Fibrosis Association consensus report criteria - Having mild (FEV1 = 70% predictive) lung disease according to the disease severity classification in the annual report of the American Cystic Fibrosis Society - To be able to produce phlegm Exclusion Criteria: - Contracture or deformity, - History of diagnosed orthopedic problems affecting mobility or musculoskeletal surgery - History of previous lung or liver transplant - Have diagnosed vision, hearing, vestibular or neurological problems that may affect balance, - History of hospitalization in the last 1 month - Patients who have participated in any exercise training program in the last 6 months

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Exercise with hippotherapy simulator
30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
Respiratory Physiotherapy
Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.

Locations

Country Name City State
Turkey Bezmialem Vakif University Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Istanbul University - Cerrahpasa (IUC)

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Forced Vital Capacity (FVC) Pulmonary Function Test 8 weeks
Primary Forced Expiratory Volume in 1 second (FEV1) Pulmonary Function Test 8 weeks
Primary Tiffeneau ratio (FEV1/FVC) Pulmonary Function Test 8 weeks
Primary Peak Expiratory Flow (PEF) Pulmonary Function Test 8 weeks
Primary Distance covered in six minute walk test Functional Capacity 8 weeks
Primary Amount of sputum expelled (gr) Sputum amount 8 weeks
Secondary Postural stability test score in Biodex Balance System SD Postural Stability 8 weeks
Secondary Limits of stability test score in Biodex Balance System SD Postural Stability 8 weeks
Secondary Sit and reach test Flexibility 8 weeks
Secondary m. quadriceps strength Peripheral Muscle Strength 8 weeks
Secondary Biering Sorenson Test Core Muscles Endurance 8 weeks
Secondary Lateral Bridge Test Core Muscles Endurance 8 weeks
Secondary Trunk Flexion Test Core Muscles Endurance 8 weeks
Secondary Physical Activity Questionnaire for Children (PAQ-C) Physical Activity Level. As a result of the 9-item questionnaire, 1 means lowest and 5 means highest physical activity level. 8 weeks
Secondary Cystic Fibrosis Questionnaire Revised (CFQ-R) Quality of Life Assessment. In this questionnaire, which consists of 35 questions, the total score is 100, and a higher score indicates a better quality of life. 8 weeks
Secondary Sense of chest congestion Subjective evaluation method questioning "sense of chest congestion" with visual analog scale (0-10 point). A higher score indicates greater sense of chest congestion. 8 weeks
Secondary Ease of expectoration Subjective assessment that evaluates "how hard the person has during sputum production" with a visual analog scale (0-10 point). A high score means that it is easy to sputum. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Completed NCT06109675 - Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status N/A
Active, not recruiting NCT04392544 - Intestinal Inflammation in CF Patients
Completed NCT04084041 - Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis N/A
Not yet recruiting NCT03292718 - Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis N/A
Not yet recruiting NCT05493137 - Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
Enrolling by invitation NCT06188988 - Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Completed NCT04138589 - Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
Completed NCT03579173 - Determinants of Early Cystic Fibrosis Lung Disease
Recruiting NCT05850351 - Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis N/A
Completed NCT04463628 - Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
Completed NCT04835376 - Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis N/A
Completed NCT04293926 - Heart Rate Variability in Children and Adolescents With Cystic Fibrosis N/A
Completed NCT04987567 - Effect of Antioxidant Docosahexaenoic Acid (DHA) in Cystic Fibrosis Patients N/A
Withdrawn NCT04415268 - Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis N/A
Not yet recruiting NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Active, not recruiting NCT04613128 - The PROMISE Pediatric Study 6 to 11 Years Old